spacer
home > pmps > spring 2017 > breathing new life into asthma care
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Breathing New Life into Asthma Care

Smart inhalers represent a convergence of several market forces, technology and trends that are poised to change asthma care and improve outcomes. They are part of an overall smart device trend in mHealth focused at the multibillion dollar asthma industry. One of the biggest culprits of poor patient outcomes in asthma care is taking a reactive rather than proactive approach to treatment, and poor adherence of care plans among patients.

Why Smart Inhalers?

The technology around these devices can offer a number of benefits to both the patient and the healthcare provider, such as making it easier to remember to take prevention medicine and report symptoms, which can lead to improved disease self-management and adherence rates. Other benefits include their ability to collect actionable data and patients being able to identify their own patterns. Sixty-seven percent of patients do not take their inhalers correctly. With smart sensors built into these devices, the patient is told if they have shaken it correctly or not.

The sensors can also detect the quality of inhalation, which is very important when it comes to judging the effectiveness of the medication. Collection of key data, recognising patterns and potential aggravators to severe asthma attacks can help reduce costly readmissions and result in improved disease management as well as adherence rates. In the future, a convergence of trends and technologies will put smart inhalers and their accompanying data at the epicentre of managing asthma care. To this end, some companies

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
An engineer at heart and entrepreneur by trade, Ali Moiyed is founder and Chief Executive Officer of Aerobit Health. Living with asthma himself, he launched the digital healthcare company in July 2016.
spacer
Ali Moiyed
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Synpromics expands facilities to meet demand for revolutionary gene control technology

Edinburgh, UK, 11th September 2017 - Synpromics Ltd, the leader in gene control and synthetic promoter development, today moves to new world-class facilities at the Roslin Innovation Centre. Synpromics is expanding to meet increasing global demand for its cutting-edge gene control technology, and is the first company to move into the new custom-built centre based at the University of Edinburgh’s Easter Bush Campus.
More info >>

White Papers

Crossing the Blood Brain Barrier (BBB): Which Route to Take?

Aptar Pharma

Aptar Pharma recently hosted an expert panel/roundtable on the various approaches to treating central nervous system (CNS) diseases. This international scientific forum was held in Paris, France on December 5th, 2014. The roundtable was organized to explore and exchange views on the challenges, approaches and opportunities that exist with regard to effectively crossing the blood brain barrier (BBB) and successfully treating a host of CNS diseases.
More info >>

 
Industry Events

Clinical Trial Supply New England 2018

7-8 March 2018, Boston, MA, USA

Clinical Trial Supply New England has now reached its 7th birthday! For the 7th annual Clinical Trial Supply New England 2018 conference, we have speakers who will focus primarily on discussing case studies, drawing from their own experiences to share the highs and lows for you to adopt in your trials.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement